Skip to main content
University of Wisconsin-Madison

Events

Events in November 2024

Sunday Monday Tuesday Wednesday Thursday Friday Saturday
October 27, 2024
October 28, 2024(3 events)


October 28, 2024

Lab Exam

See syllabus for location


October 28, 2024

This event runs from 4:30 on 10/28/24 to 12 Noon on 10/29/24.

 

 

Online

October 29, 2024(4 events)


October 29, 2024

The Office of Global Health and the Office of Diversity, Equity, and Inclusion presents the panel discussion: Bridging Gaps: Disability Awareness and Patient-Centered Care in Pharmacy

Tuesday, October 29th at noon Room 2006

Event Description: This event aims to equip pharmacists and aspiring pharmacists with the knowledge to better assist patients with disabilities, promote healthcare accessibility, and reduce healthcare disparities. Following a movie preview on your own (the movie will be announced soon), join our panelists for a discussion on how to best interact with and provide healthcare to people living with disabilities.

Panelists:

  • Leslie Stilson, McBurney Resource Specialist: Lived experiences with visual impairment.
  • Elsa Thiel, high school student: Lived experience with Guillain-Barre Syndrome post vaccination.
  • Julie Thiel, PharmD and mother of Elsa. Lived experience advocating for her daughter.
  • Amy Elske, Aging Disability Resource Center. Resource specialist for people living with disabilities in Dane County.
777 Highland Ave
Madison, WI 53705
United States


October 29, 2024

This event runs from 4:30 on 10/28/24 to 12 Noon on 10/29/24.

Online


October 29, 2024

Lab Exam

See syllabus for location


October 29, 2024

 This event runs from 4:30 PM 10/29/24 to 12 Noon on 10/30/24. 

Online

October 30, 2024(3 events)


October 30, 2024

 This event runs from 4:30 PM 10/29/24 to 12 Noon on 10/30/24. 

Online


October 30, 2024

Lab Exam

See syllabus for location


October 30, 2024

 This event runs from 4:30 PM 10/30/24 to 12 Noon on 10/31/24. 

Online

October 31, 2024(2 events)


October 31, 2024

 This event runs from 4:30 PM 10/30/24 to 12 Noon on 10/31/24. 

Online


October 31, 2024

Lab Exam

See syllabus for location

November 1, 2024(2 events)

November 1, 2024

Block 4 runs from September 23 to November 1, 2024 .

Online


November 1, 2024

Pharmaceutical Sciences Seminar Series

 

(Drug DISCOVERY Specific Seminar)

  • Kathie Seley-Radtke, PhD
  • University of Maryland

Development of Pan-Viral Nucleoside Inhibitors

The severity and rapid spread of the coronavirus pandemic served to drive home that we were completely unprepared to fight such an outbreak. As a result, it became clear that there was a critical need for small molecule, orally bioavailable, broad-spectrum drugs that could be stockpiled and readily distributed when the next outbreak occurs. In that regard, for many years nucleos(t)ides have maintained a prominent role as one of the cornerstones of antiviral and anticancer therapeutics, and numerous scaffolds in nucleos(t)ide and nucleic acid drug design have been pursued. One such approach involves adding flexibility to the sugar moieties of nucleos(t)ides, for example, in the highly successful anti-HIV/HBV drug Tenofovir developed by Antonín Holý. In contrast, introduction of flexibility to the nucleobase scaffold has only more recently gained significance with the invention of our fleximers. This modification has led to a significant improvements in antiviral activity, and in some cases endowing the nucleoside with potent broad-spectrum activity across several viral families, when the parent rigid nucleoside was inactive. Another advantage observed is the ability to avoid resistance mechanisms related to point mutations by engaging secondary amino acid residues not previously involved in the mechanism of action. A second series of nucleosides being pursued in our group, involves insertion of a heterocyclic spacer ring in between the two moieties of the bicyclic purine ring system, forming an expanded tricyclic nucleoside with increased aromaticity. This modification has also led to potent antiviral activity, again targeting several different pathogens of pandemic concern. A brief history of their design, synthesis, and recent antiviral findings for these innovative nucleos(t)ide scaffolds will be discussed.

Hosted by Jennifer Golden

777 Highland Ave
Madison, WI 53705
United States

November 2, 2024
November 3, 2024
November 4, 2024(2 events)

November 4, 2024

Block 5 runs from November 4 to December 20, 2024. 

Online


November 4, 2024

 This event runs from 4:30 PM 11/4/24 to 12 Noon on 11/5/24. 

Online

November 5, 2024(2 events)


November 5, 2024

Exam

2002 and 2006 Rennebohm Hall
777 Highland Ave.
Madison, WI 53705
United States


November 5, 2024

 This event runs from 4:30 PM 11/4/24 to 12 Noon on 11/5/24. 

Online

November 6, 2024(1 event)


November 6, 2024

This event runs from 4:30 PM on November 6 to 12 Noon on November 7th.

Online

November 7, 2024(2 events)


November 7, 2024

This event runs from 4:30 PM on November 6 to 12 Noon on November 7th.

Online


November 7, 2024

This event runs from 4:30 PM on November 7 to 12 Noon on November  8th. 

Online

November 8, 2024(2 events)


November 8, 2024

This event runs from 4:30 PM on November 7 to 12 Noon on November 8th. 

Online


November 8, 2024

Pharmaceutical Sciences Seminar Series

(Drug ACTION Specific Seminar)

  • Nan Gao, PhD
  • Rutgers University

Non-canonical Paneth cell functions regulate intestinal inflammatory response

Paneth cells are the primary source of C-type lysozyme, a β-1,4-N-acetylmuramoylhydrolase that enzymatically processes bacterial cell walls. Aberrant lysozyme production are hallmarks of inflammatory bowel disease (IBD) pathology. I will show experiments that demonstrate the impact of lack or ectopic lysozyme production on colonic inflammation. I will also show data about how Lyz1-deficiency modulates the gut bacterial composition and intestinal immune responses to bacterial molecular patterns. I will present biochemical and immunology evidence to suggest that Paneth cell lysozyme balances intestinal anti- and pro-inflammatory responses.

In addition, I will shed light on our recent finding that a direct engagement of intestinal lysozyme with enteric pathogens such as Salmonella promotes the release of bacterial virulence factors that are barrier-impairing and pro-inflammatory.

In the end I’ll discuss our ongoing work investigating the Paneth cell subsets that may be important for host responses to infection and inflammation.

Hosted by Ting Fu

777 Highland Ave
Madison, WI 53705
United States

November 9, 2024
November 10, 2024
November 11, 2024
November 12, 2024(1 event)
November 13, 2024(1 event)


November 13, 2024

Exam

2002 and 2006 Rennebohm Hall
777 Highland Ave.
Madison, WI 53705
United States

November 14, 2024
November 15, 2024(1 event)


November 15, 2024

2024 WARF Therapeutics Distinguished Lecture in Drug Discovery

  • Jeffrey Aubé, PhD
  • University of North Carolina

New Approaches to Tuberculosis Therapeutics

Tuberculosis (TB) continues to be a major worldwide health problem, despite the existence of numerous drugs for its treatment. This is in part due to the long therapeutics times required to administer cocktails of front-line therapeutics and in part due to the emergence of even more challenging long-term strains. For these reasons, new therapeutic agents for the treatment of TB continue to be sought. In collaborative work with the laboratory of Carl Nathan (Weill–Cornell Medicine) and others, we have sought to find new chemotypes as potential anti-TB agents and to identify new biochemical targets for drug treatment. In this talk, I will describe our efforts in this area, beginning with early approaches to explore beta-lactam antibiotics as possible TB agents. More recent efforts have been focused on finding inhibitors of phosphopantetheinyl transferase (PptT). PptT carries out central biochemistry that is essential for mycobacterial survival; for this reason, it has been a long sought-target for antibacterial agent development. This story begins with our team’s discovery of the first effective small-molecule inhibitors of PptT, efforts to use bioisostere design to create a new series, and more recent chemotypes of PptT.

Hosted by Jennifer Golden


Portrait: Jeffrey Aube, PhD

Jeffrey Aubé, PhD
Esehlman Distinguished Professor
Division of Chemical Biology & Medicinal Chemistry
Eshelman School of Pharmacy, University of North Carolina at Chapel Hill

Jeffrey Aubé attended the University of Miami, where he did undergraduate research with Professor Robert Gawley. He received his Ph.D. in chemistry in 1984 from Duke University, working with Professor Steven Baldwin, and was an NIH postdoctoral fellow at Yale University with Professor Samuel Danishefsky. From 1986 until 2015,he held a faculty position in the Department of Medicinal Chemistry at the University of Kansas. In 2015, he moved to the University of North Carolina, where he is an Eshelman Distinguished Professor in the Division of Chemical Biology and Medicinal Chemistry and holds a joint appointment in the Department of Chemistry.

777 Highland Ave
Madison, WI 53705
United States

November 16, 2024
November 17, 2024
November 18, 2024(2 events)


November 18, 2024

This event starts at 5 PM on November 18 and ends on December 6th at 11:55 PM 

Online

November 19, 2024
November 20, 2024
November 21, 2024
November 22, 2024(1 event)
November 23, 2024
November 24, 2024
November 25, 2024
November 26, 2024
November 27, 2024
November 28, 2024
November 29, 2024
November 30, 2024